Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum

University of Missouri (MU)

Status: Completed

Conditions: Type 2 Diabetes

Treatments: Other: Normoxia Exposure; Other: Hyperoxia Exposure

Study type: Interventional

Funder types: Other

Identifiers

NCT05219994

2018486

Details and patient eligibility

About

Our overall goal is to advance our understanding of the contribution of the carotid body chemoreceptors in glucose regulation and the development of type 2 diabetes.

Enrollment: 22 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy,
• type 2 diabetes
• BMI 18-40 kg/m2,
• non-pregnant,
• non-breastfeeding,
• non-nicotine users.

Exclusion criteria

• cardiovascular disease including myocardial infarction, heart failure, coronary artery disease, stroke;
• renal or hepatic diseases;
• active cancer;
• autoimmune diseases;
• immunosuppressant therapy;
• excessive alcohol consumption (>14 drinks/week);
• current nicotine use;
• foot ulcers;
• diabetic neuropathy;
• medication directly influencing sympathetic nervous system activity

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

22 participants in 1 patient group

Oral Glucose Tolerance Test

Experimental group

Description:

Subjects will consume a 75 g glucose drink within 1-min and monitored for 2 hours.

Treatment:

Other: Hyperoxia Exposure

Other: Normoxia Exposure